CytomX Therapeutics Competitors and Similar CompaniesClear all
CytomX Therapeutics's competitors and similar companies include Stingray Therapeutics, SQZ Biotech and Ablynx.
 CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Stingray Therapeutics Stingray Therapeutics is a company that specializes in immunotherapy to fight cancer. |  SQZ Biotech SQZ Biotechnologies is a company that develops cell therapies for patients with cancer and infectious diseases. |  Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | |
Founding Date | Founding Date 2008 | Founding Date 2018 | Founding Date 2013 | Founding Date 2001 |
Type | Type Public | Type Private | Type Public | Type Subsidiary |
Tags | ||||
Locations | Locations South San Francisco, US HQ | Locations Houston, US HQ | Locations Watertown, US HQ | Locations Gent, BE HQ |
Employees | Employees 15815% increase | Employees 6 | Employees 5353% decrease | Employees 156 |
Valuation ($) | Valuation ($) 87.5 m | Valuation ($) N/A | Valuation ($) 12.8 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $101.2m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $21.5m (FY, 2022) | Revenue (est.) €85.2m (FY, 2016) |
Net income | Net income ($569k) (FY, 2023) | Net income N/A | Net income ($79.5m) (FY, 2022) | Net income (€1.1m) (FY, 2016) |
Operating ⚠ | ||||
Patents (Foreign) | Patents (Foreign) 4 (FY, 2016) | Patents (Foreign) N/A | Patents (Foreign) N/A | Patents (Foreign) 180 (Q2, 2017) |
Patents (US) | Patents (US) 13 (FY, 2016) | Patents (US) N/A | Patents (US) N/A | Patents (US) 50 (Q2, 2017) |
Phase I Trials Products | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 1 (Q2, 2020) | Phase I Trials Products N/A |
Pre-Clinical Phase Products | Pre-Clinical Phase Products 4 (FY, 2016) | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 10 (Q2, 2020) | Pre-Clinical Phase Products N/A |
Funding | ||||
Total funding raised | Total funding raised $ 132.4m | Total funding raised N/A | Total funding raised $ 233.4m | Total funding raised $ 498.8m |
For sources of this data, please see the company profile
View Company Profiles
Stingray Therapeutics
HQ
Houston, US
Employees
6
Stingray Therapeutics is a company that specializes in immunotherapy to fight cancer.
View companySQZ Biotech
HQ
Watertown, US
Employees
53
SQZ Biotechnologies is a company that develops cell therapies for patients with cancer and infectious diseases.
View companyAblynx
HQ
Gent, BE
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company